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www.co-clinicalnutrition.com´ a a bElvira Larque , Marı́a Ruiz-Palacios , and Berthold KoletzkoPurpose of review
Placental nutrient uptake and transfer may have a unique role, as changes in trophoblast nutrient-sensing
signaling pathways regulate cell metabolism and may affect the fetal growth and health programming in
the offspring.
Recent findings
The functionality of the placenta could affect the neonatal adiposity and the fetal levels of key nutrients such
as long-chain polyunsaturated fatty acids. Insulin, oxygen and amino acid concentrations may regulate the
mammalian target of rapamycin (mTOR) nutrient sensor in the human placenta affecting trophoblast
metabolism and nutrient delivery.
Summary
The mechanisms involved in both placental uptake and transfer of macronutrients are reviewed. Fatty acid,
cholesterol and amino acid transport across the placenta involves a complex system to ensure nutrient
delivery to the growing fetus. The placental glucose transfer is important for fetal macrosomia, but lipid
disturbances in both maternal and placental compartments may contribute to neonatal fat accretion.
Maternal insulin has little effect on the avidity of glucose transport by the placenta, but may interfere in
placental metabolism via mTOR nutrient sensor. mTOR is a positive regulator of the amino acid carriers
and constitutes a critical link between maternal nutrient availability and fetal growth, thereby influencing
the long-term health of the fetus.
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The intrauterine development of the fetus depends
on an adequate nutrient supply via the placenta.
This is not achieved by simple diffusion of all
substrates, but the transfer of some nutrients is
regulated by the placenta itself. Some nutrients
and substrates are metabolized by the placenta,
and the placental expression of specific transport
proteins appears to be adapted to fetal demands. The
regulation of placental enzymes, receptors and
transport proteins will determine the extent of
glucose, lipids and amino acid transfer to the fetus
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PLACENTAL GLUCOSE TRANSFER
Glucose is the main source of energy for the fetus,
although lipids also play an important role. In preg-
nant women infused with glucose labeled with
stable isotopes some hours before delivery, it was
shown that over 95% of fetal plasma glucose was
derived from maternal plasma [1].iams & Wilkins. UnauthoThe placental glucose transport occurs by facili-
tated diffusion mediated mainly by the glucose
carrier GLUT-1, which is a carrier independent of
insulin. GLUT-1 has been identified in the placental
trophoblast cells with an asymmetrical distribution,
being more abundant in the microvillous mem-
brane (maternal face) in contrast to the basal mem-
brane (fetal face). This asymmetrical distribution
has been proposed as a rate-limiting step in the
transplacental glucose transfer from the mother to
the fetus [2]. In gestational diabetes mellitus (GDM),
enhanced levels of GLUT-1 in the basal membrane
of the placenta were reported which could lead to a
higher transfer of glucose to the fetal circulation.rized reproduction of this article is prohibited.
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KEY POINTS
 Glucose and lipid metabolism may interfere with amino
acid transport through nutrient signal pathways.
 Placental tissue uptakes preferentially long-chain
polyunsaturated fatty acids (LC-PUFAs) with respect to
other fatty acids, but the mechanisms involved in this
preferential transfer should be clarified in healthy and
pathological pregnancies.
 There is a competition for placental cholesterol uptake
from the maternal lipoproteins by different carriers, but
the relevance of each cholesterol carrier in the whole
materno-fetal transfer process is yet unknown.
 Insulin
 O2
 ATP  AMPK
 Protein synthesis





FIGURE 1. Signaling mechanisms of mTOR and link
between maternal nutrient availability and fetal growth.
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expression is relatively refractory to glucose concen-
tration. Moreover, GLUT-3 is present in the endo-
thelial walls of umbilical arteries and recently it has
been described also in placental syncytial micro-
villous membrane [3]. GLUT-3 shows high expres-
sion in placenta early in gestation, decreasing at the
end of pregnancy [4]. In fact, GLUT-3 mutations
cause early pregnancy loss and fetal growth restric-
tion [5]. The different expression of GLUT-3 in
placenta along gestation has been proposed to be
associated with the local changes of CRH synthesis
by the placenta [3], although other mechanisms
could be also implicated. Interestingly, brain and
placental tissue both are dependent upon these two
glucose transporter (GLUT) isoforms GLUT-1 and
GLUT-3 for glucose uptake, which are not insulin
responsive.
The role of GLUT-4 in the placental glucose
transfer is uncertain. GLUT-4 (which is the main
glucose carrier in the organism and that depends on
insulin) has only been identified in the stroma of the
placental villous, but not in syncytiotrophoblast
cells. Recently, some fructose-specific transporters
like GLUT-9 and GLUT-11 or even GLUT-10 and
GLUT-12 have also been identified in placental
tissue, but their role in regard to glucose transport
remains uncertain [6]. Epigenetic studies indicate
that DNA methylation regulates the expression of
GLUT-3 and GLUT-10 during gestation, whereas
the constitutively expressed GLUT-1 showed no
promoter methylation [7].
Insulin and protein hormones do not cross
placental tissue. Maternal insulin has little effect
on the avidity of glucose transport by the placenta,
but interfere modifying glucose levels in maternal
circulation [8]. The role of insulin in the placental
glucose uptake is very limited, as syncytiotropho-
blast do not express GLUT-4 carriers. Nevertheless,
the activation of the insulin receptor in the placentaCopyright © Lippincott Williams & Wilkins. Unau
1363-1950  2013 Wolters Kluwer Health | Lippincott Williams & Wilkupregulate the nutrient sensor signal, mammalian
target of rapamycin (mTOR) [9
&
]. mTOR is a positive
regulator of placental amino acid transporters and
stimulates cell proliferation and growth, promoting
an anabolic metabolic phenotype Fig. 1 (mTOR
signaling). Preliminary studies indicate an acti-
vation of placental mTORC1 signaling in associ-
ation with maternal obesity [10
&
] and probably
with GDM, which could link insulin levels in these
patients. This could explain in part the higher size of
GDM placentas with respect to the controls classi-
cally described. Nevertheless, there is also a down-
regulation of the insulin signal pathway by insulin
receptor internalization via Annexin A2 in GDM
placental villi, leading to insulin resistance even
in GDM placentas [11].
The placenta can also partially regulate its
glucose level by the synthesis of glycogen. Although
some gluconeogenic enzymes were known to be
present, the placenta was previously considered
incapable of glucose secretion because it lacked
glucose-6-phosphatase. However, further studies
have demonstrated that specific glucose-6-phospha-
tase is present in the placenta, but it may be the
product of a different gene from conventional
hepatic glucose-6-phosphatase. GDM placentas
have abundant depots of glycogen in its structure
pointing to another mechanism of glucose transfer
modulation [12].
Fetal macrosomia and its complications may
occur even in adequately controlled diabetic
mothers, suggesting that maternal glycemia is not
the only determinant of fetal glycemic status and
well-being. Both maternal triglycerides and non-
esterified fatty acids (NEFAs) levels have been shown
to be correlated with both neonatal weight and fat
mass in GDM, indicating that maternal hyperlipi-
demia in GDM actively enhances the availability of
lipids to the fetus [13]. The underlying mechanismsthorized reproduction of this article is prohibited.
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Paediatricsby which maternal hyperglycemia regulates placen-
tal lipid metabolism and translate into fetal adi-
posity are incompletely understood.MECHANISMS INVOLVED IN THE
PLACENTAL TRANSFER OF FATTY ACIDS
There is a relatively high placental transfer of lipids
in humans, and even the fetus may synthesize some
saturated fatty acids and monounsaturated fatty
acids from glucose. Lipids are transferred because
the fetus requires essential linoleic and a-linolenic
acid, and additionally long-chain polyunsaturated
fatty acids (LC-PUFAs) to match the in-utero accre-
tion rate especially during the brain growth spurt.
It has been demonstrated in pregnant women
in vivo, using labeled fatty acids with stable isotopes,
the preferential placental uptake and transfer of
LC-PUFAs from the mother to the fetus with respect
to other fatty acids, and specially for docosahexae-
noic acid (DHA; n-3 LC-PUFA) [14,15]. This selective
LC-PUFA transfer highlights the relevance of the
placenta for the fatty acid transfer. In addition,
maternal and offspring fatty acid desaturase (FADS)
polymorphisms may contribute to determine cord
blood n-6 LC-PUFAs, whereas the association with
n-3 LC-PUFAs is weaker [16]. It cannot be discarded
that fetus could synthesize additional DHA by itself,
which might be necessary to satisfy the high fetal
demand of DHA during pregnancy.
The mechanisms involved in the placental
uptake and transfer of fatty acids were recently
reviewed by our group [17
&&
]. In the placenta, two
lipases have been until now identified for major
fatty acid release from the maternal circulating
lipoproteins: lipoprotein lipase (LPL) and endothelial
lipase. LPL shows triglyceride lipase activity, whereas
endothelial lipase is a phospholipase with little tri-
acylglycerol lipase activity. At the end of pregnancy,
endothelial lipase continues to be expressed, whereas
LPL is virtually absent in the trophoblast. In addition,
maternal circulating NEFAs can be directly uptaken
from the placenta.
Numerous membrane-bound proteins are
expressed in the trophoblast: fatty acid binding
protein plasma membrane (FABPpm), placental
plasma membrane fatty acid-binding protein
(p-FABPpm), fatty acid translocase (FAT/CD36) and
fatty acid transport proteins (FATP-1 to FATP-6)
[17
&&
]. Only p-FABPpm seems to be exclusive to
placental tissue [18], but this protein has not been
genetically sequenced and more evidences on the
function and identification of this protein are
needed. Once in the cytosol, fatty acids are bound
to cytosolic fatty acid binding proteins (FABPs) to
interact with subcellular organelles, including theopyright © Lippincott Williams & Wilkins. Unautho
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and peroxisomes. FABPs are also likely to function in
the nucleus through the delivery of specific ligands to
nuclear transcription factors, such as the peroxisome
proliferator-activated receptors (PPARs) [17
&&
].
Several studies suggest that the placental uptake
of maternal fatty acid is altered by maternal over-
nutrition. Analysis of human placental lipids has
shown that the content of triglycerides is higher in
placentas from diabetic pregnancies [19]. Neverthe-
less, available results on the placental LPL and
endothelial lipase levels in GDM patients are incon-
clusive, maybe because of the low number of patients
in such studies; no changes [20,21], increases in
endothelial lipase but not in LPL [19], increases in
LPL [22
&
] and even reduction in placental LPL [23], to
counteract excessive placental uptake of fatty acids
in GDM was reported. Activation of several genes
involved in the placental lipid biosynthetic pathways
was also reported in the placenta GDM [23], although
a decrease in the fatty acid oxidation rate could be
also responsible for the enhanced fat store in the
placental lipid droplets of GDM.
The relationship between fatty acid carriers and
the placental fat storage on GDM is complex because
of the numerous fatty acid carriers implicated.
Increases in placental membrane carriers FAT/
CD36 and decreases in FATP-4, H-FABP and L-FABP
carriers were reported in GDM placenta [22
&
]. Fatty
acid incorporation in placental lipid droplets may
also interfere in their rate of fetal transfer. In fact, in
GDM, a significant discrepancy between normal
LC-PUFA contents in erythrocyte and plasma phos-
pholipids of the mother but reduced LC-PUFA con-
tents in plasma phospholipids of the neonate was
found [24,25]. These data suggest that LC-PUFA
transport from the placenta to the fetal circulation
could be impaired in women with gestational dia-
betes. It is important to discern the reason for the
lower levels of DHA in GDM babies in order to
identify the best strategy of supplementation with
LC-PUFA in the mother, the baby or both.CHOLESTEROL PLACENTAL TRANSFER
During the last trimester of pregnancy, maternally
derived cholesterol contribute with an average of
about 22–40% to the fetal cholesterol pool [26].
The remaining placental cholesterol, however, is
used for sterol synthesis, foremost of progesterone.
Maternal hypercholesterolemia may lead to prescle-
rosis lesions already in the fetus which raised
the interest for understanding the mechanisms
involved in the placental transfer of this cholesterol
to design suitable pharmacological treatment in
these patients [27].rized reproduction of this article is prohibited.













FIGURE 2. Mechanisms involved in the cholesterol transfer
across the placenta. Lipoprotein receptor (Lipoprotein R),
scavenger receptor class B type 1 (SR-B1), lipoprotein
related protein (LRP), ATP-binding cassette (ABC) transporters
ABCA1 and ABCG1, non-esterified fatty acids (NEFA).
Placental regulation of fetal nutrient supply Larqué et al.Maternal cholesterol can be taken up by the
trophoblasts using a lipoprotein-receptor-mediated
mechanism (LDL receptor and VLDL-receptor) that
requires endocytosis of the particle to lysosomes/
endosomes (Fig. 2); the receptor is recycled to the
membrane, whereas the free cholesterol is trans-
ported across the cells to metabolically active pools
or membranes via Niemann-Pick C1 (NPC1) or other
less well defined sterol carrier proteins, like NPC1L1
and SPC-x/2 (sterol carrier protein) [28
&
]. The endo-
cytosis could also provide fatty acids to the placental
tissue by the action of intracellular lipases on the
lipoprotein, but the relevance of this mechanism for
the placental uptake of fatty acids is still uncertain.
In addition to this transport mechanism, cho-
lesterol uptake is also mediated by other receptors
that only transfer the cholesterol across the plasma
membrane without internalization of the receptor
(Fig. 2). In this way, scavenger receptor class B (SR-
B1) binds cholesterol mainly from HDL and with less
affinity of LDL or modified LDL; LDL-receptor
related protein (LRP-1) binds apolipoprotein-E-con-
taining particles such as VLDL. Cubilin and megalin
[also named lipoprotein-related protein 2 (LRP-2)]
act in concert to bind both HDL and LDL, cubilin
binds apo A-1, whereas megalin binds Apo E and
Apo B [28
&
]. ATP-binding cassette (ABC) transporters
ABCA1 and ABCG1 mediate the efflux of cholesterol
across cellular membranes and removes excess
cellular cholesterol [29]. The distribution of ABC iso-
forms in apical or basal localization is controversial
[30–32]. ABC and SR-B1 seem to be also involved in
the cholesterol efflux to fetal lipoproteins [28
&
,33].
Oxysterols formed during cholesterol synthesis
as well as by the oxidation of dietary cholesterol may
enhance the expression of placental ABCA1 andCopyright © Lippincott Williams & Wilkins. Unau
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Treatment of mice with Smith–Lemli–Optiz syn-
drome (dysfunction on the de novo synthesis
of cholesterol) using LXR agonists increases the
placental ABCA1 carriers and the materno-fetal
cholesterol transfer to the embryos increasing the
placental cholesterol efflux [29]. Moreover, low
oxygen, like in preeclampsia, increase LXR and
ABCA1 carriers which may have consequences for
maternal–fetal cholesterol transport [34].
Intrauterine growth restriction (IUGR) is associ-
ated with alterations in maternal and fetal lipopro-
teins. Few studies have evaluated the expression
pattern of cholesterol receptors, but the results
are controversial. The differential changes in
LDL-R and SR-B1 reported in the IUGR placentas
warrant further investigations to clarify placental
cholesterol uptake in healthy and pathological
pregnancies [35].MECHANISMS INVOLVED IN THE
PLACENTAL AMINO ACID TRANSFER
The size of proteins is the limiting key factor regard-
ing the uptake and transfer of proteins across the
placenta. There is no relevant transfer of protein
hormones across the placenta, for example, pancre-
atic or pituitary hormones. Nevertheless, the trans-
fer of free amino acids across the placenta is essential
for fetal growth, and the disturbed transfer is associ-
ated with IUGR babies. Free amino acid concen-
tration in the placental tissue exceeds by far those
of the maternal or fetal circulation which suggest a
major role of the placenta in this process.
Amino acids are transferred across the placenta
by active transport using a complex system with
more than 10 different families of amino acid
carriers: systems A, L, yþ, yþL, T, X-AG and ASC
(Table 1) [36,37]. These carriers can be classified in
two classes: accumulative amino acid transporters
(mainly represented by system A and X-AG) and
amino acid exchangers (LAT1, LAT2, yþLAT1,
yþLAT2 and ASC) [37]. Accumulative amino acid
transporters mediate net uptake of specific amino
acids into the syncytiotrophoblast. However, amino
acid exchange transporters swap one amino acid
within the syncytiotrophoblast for the one in the
maternal or fetal circulation, thus altering the com-
position but not the overall quantity of amino acids
transported. Recently, another novel transport
system has also been identified, amino acid efflux
carriers, that transports amino acids only from the
placental cytosol into the fetal circulation [38].
Unlike other transporters, efflux transporters may
increase the fetal amino acid concentrations, and
the expression of placental LAT3 and TAT1 effluxthorized reproduction of this article is prohibited.
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Table 1. Amino acid transport system in the human placenta
Transport system Mechanism Protein Localization Substrate
Naþ-dependent systems
A ACC SNAT1,2,4 MVM, BM Neutral amino acids
ASC EX ASCT1,2 BM Neutral amino acids
b TAUT MVM, BM Taurine
N SN1 MVM (contested in humans) Histidine, asparagine, glutamine
X-AG ACC/EX EAAT1-4 MVM, BM Anionic amino acids
GLY GLYT1 MVM Glycine and sarcosine
B0,þ ATB0,þ ? Cationic and neutral amino acids
Naþ-independent systems
L EX/EF LAT1,2,4/4F2hc MVM, BM Neutral amino acids, branched-chain
amino acids and tryptophan
yþ Uniporter CAT1,4 MVM, BM Cationic amino acids
yþL EX yþLAT1/4F2hc MVM, BM Cationic amino acids (neutral amino
acids in the presence of sodium)
b0,þ EX rBAT BM Cationic and neutral amino acids
T EF TAT1 BM Aromatic amino acids
Asc EX asc1/4F2hc BM? Small neutral amino acids and D-serine
ACC, accumulative; BM, basal membrane; EF, efflux; EX, exchange; MVM, microvillous membrane. Data from [36] and [37].
Paediatricscarriers has shown positive associations with the
infant size at birth [38]. Moreover, amino acids
may also be metabolized within the placenta, and
glutamate is converted in glutamine, or even can be
transferred through the fetal circulation. Altogether,
these observations point to a complex system to
facilitate nutrient delivery to warrant the demand
of the growing fetus.
Insulin, oxygen and amino acid concentrations
may regulate mTOR nutrient sensor in the human
placenta (Fig. 1). mTOR is a positive regulator of
the amino acid carriers system A and system L [39].
mTOR activity is inhibited in the IUGR placentas
consistent with the possibility that the nutrient
and oxygen levels are low in the trophoblast
(Fig. 1) [40]. On the contrary, it was reported that
activation of placental mTOR signaling and amino
acid transporters in obese women give birth to
large babies [10
&
]. Maternal adiponectin levels
decrease with maternal obesity and are inversely
correlated to birth weight; chronic maternal infu-
sion of adiponectin in pregnant mice downregu-
lated the placental amino acid transporters and
decreased the fetal growth [41
&
]. This effect was
mediated by the inhibition of insulin/IGF-1 and
mTOR signaling pathways linking another novel
physiological mechanism by which the endocrine
functions of maternal adipose tissue influence
fetal growth. In other words, the placenta acts
as a ‘nutrient sensor’ regulating its transporter
function.opyright © Lippincott Williams & Wilkins. Unautho
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placental transport of other key molecules such as
thyroid hormones T3 and T4 by a putative system T
and system L transporters. In addition, systems L, A
and y(þ)L are involved in placental homocysteine
(Hcy) transport [42]. Elevated maternal plasma
levels of Hcy are associated with pregnancy compli-
cations and adverse neonatal outcomes, suggesting
placental transport of Hcy may impact on fetal
development.CONCLUSION
Placental tissue is dependent upon GLUT isoforms
for glucose uptake that are not insulin responsive.
Insulin upregulates mTOR in the placenta and inter-
feres with the amino acid uptake and cell growth.
Higher placental lipid droplet accumulation and
impaired LC-PUFA transfer was reported in GDM
which might adversely affect the offspring. The
placental cholesterol is mainly used for steroid
hormone synthesis and also for fetal transfer. The
relevance of each cholesterol carrier should be
clarified. It is possible that the trophoblast mTOR
signaling links maternal nutrient availability to fetal
growth by modulating the flux of amino acids across
the placenta.
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